Business
ADOCIA Reports First Quarter 2025 Financial Results and Provides a Business Update
LYON, France, May 14, 2025--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the first quarter of 2025 and provides a business update.
About this update from Adocia Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3539,"height":1431,"url":"https://media.zenfs.com/en/business-wire.com/7d952cd4100b0c16c444ff5b4a81afe2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UCCneGmu7GguQX_7QWYS0w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM4ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/7d952cd4100b0c16c444ff5b4a81afe2","width":960,"height":388},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/4sGf8Q3UBriPI98xVjEWNA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05NzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/7d952cd4100b0c16c444ff5b4a81afe2","width":1200,"height":485}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Cash position of €12.2 million as of March 31, 2025, including €9.7m from the private placement successfully completed in February 2025","length":135,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Cash runway extended until Q2 2026","length":34,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Top-line data from Phase 3 BioChaperone® Lispro studies in China on track for mid-2025 readout to be followed by submission for Chinese regulatory review in 2025","length":161,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Business priority for 2025 remains establishing partnerships for M1Pram with Sanofi and for BioChaperone® CagriSema","length":115,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"New AdoShell® data presentations at scientific conferences showcase potential curative treatment for Type 1 Diabetes","length":116,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":561,"olType":false},{"type":"text","content":"LYON, France, May 14, 2025--(BUSINESS WIRE)--Regulatory News:","length":61,"tagName":"p"},{"type":"text","content":"Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the first quarter of 2025 and provides a business update.","length":320,"tagName":"p"},{"type":"text","content":""Our strategic priority remains securing partnerships for BioChaperone® CagriSema an...